Results 1 to 10 of about 5,574 (244)
Exploring Stakeholder Perceptions and Experience of Biosimilar Insulin Switching: A Scoping Review [PDF]
Endocrinology, Diabetes & MetabolismBackground The option to switch patients to more cost‐effective biosimilar insulins has been available since 2014, and the market share for these medicines has been slowly increasing since then. This scoping review aimed to identify the current knowledge
Ben Hindley +4 more
doaj +2 more sources
Portuguese Position Paper on the Use of Biosimilars in Psoriasis [PDF]
Acta Médica Portuguesa, 2016 Keywords: Biological Agents; Biosimilar Pharmaceuticals; Portugal; Psoriasis/drug therapy.
Tiago Torres +15 more
doaj +4 more sources
Expected Impact of Biosimilars on the Pharmaceutical Companies.
Iranian journal of medical sciences, 2021 In the last three decades, biological products have gradually developed to be an essential basis in the pharmaceutical industry. Advancements in this field have encouraged the frontiers of science to bring life-saving treatments to patients suffering from incurable diseases, such as cancers and has also assisted clinicians in managing chronic diseases ...
Golshani, Shiva, Faramarzi, Mohammad Ali
openaire +3 more sources
Pharmaceutics, 2023 Background: Limited pharmacotherapy and the failure of conventional treatments in complex pathologies in children lead to increased off-label use of rituximab.
Natalia Riva +10 more
doaj +1 more source
Comparative safety assessments of the biosimilar APZ001 and Erbitux in pre-clinical animal models [PDF]
Acta Cirúrgica Brasileira, 2018 Purpose: To evaluate the toxicity of Erbitux as well as its biosimilar APZ001 antibody (APZ001) in pre-clinical animal models including mice, rabbits and cynomolgus monkeys.
Xiaofei Wang +7 more
doaj +2 more sources
Pharmaceuticals, 2020 Drug budget and prescription control measures are implemented regionally in Germany, meaning that the uptake of pharmaceuticals, including biosimilars, can vary by region.
Evelien Moorkens +8 more
doaj +1 more source
Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure [PDF]
Frontiers in Pharmacology, 2021 Introduction: Biosimilar medicines are considered promising alternatives to new biologicals with high price tags. The extent of savings resulting from biosimilar use depends on their price and uptake, which are largely shaped by pricing, reimbursement, and demand-side policies.
Vogler, Sabine +4 more
openaire +4 more sources
Characterization of Pharmaceutical IgG and Biosimilars Using Miniaturized Platforms and LC-MS/MS [PDF]
Current Pharmaceutical Biotechnology, 2016 Therapeutic monoclonal antibodies (mAbs) have made a tremendous impact in treating patients with various diseases. MAbs are designed to specifically target a cell and illicit a response from the immune system to destroy the cell. As originator mAb drug patents are coming to an end, generic pharmaceutical companies are poised to replicate and produce so-
Kerry M, Wooding +2 more
openaire +2 more sources
The Korean Journal of Gastroenterology, 2019 Background/Aims: Current knowledge and viewpoints regarding biosimilars among physicians in Asia are unknown, even though these were investigated by European Crohn’s and Colitis Organization (ECCO) members in 2013 and 2015.
Soo-Kyung Park +4 more
doaj +1 more source
Systematic Reviews, 2021 Background Biologic drugs such as adalimumab, etanercept, and infliximab represent major first-line and second-line treatments for rheumatoid arthritis (RA) patients. However, their high cost poses a massive burden on healthcare systems worldwide.
Bruna O. Ascef +6 more
doaj +1 more source